Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Ltd has witnessed a significant improvement in its valuation parameters, shifting from a previously very expensive rating to a very attractive one. This change comes despite the company’s recent underperformance relative to the Sensex and peers in the Pharmaceuticals & Biotechnology sector, highlighting a compelling opportunity for investors to reassess the stock’s price attractiveness based on its current financial metrics and market positioning.

Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 April 2026, providing investors with the latest insights into the company’s performance and outlook.

For the fifth consecutive session, Gujarat Terce Laboratories Ltd closed lower, slipping to a fresh 52-week low of Rs 29 on 30 Mar 2026. This marks a steep 21.11% decline over the past five days amid heightened volatility and persistent selling pressure.

Despite a broader market rally, Gujarat Terce Laboratories Ltd has plunged to a fresh 52-week low of Rs 33 on 27 Mar 2026, marking a steep 43.45% decline over the past year and underscoring persistent headwinds for this micro-cap pharmaceutical player.

While the broader market surged with the Sensex climbing over 900 points, Gujarat Terce Laboratories Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 34.85 on 25 Mar 2026. The stock has now declined for three consecutive sessions, shedding nearly 13% in that period, markedly underperforming its sector and the wider market.

Gujarat Terce Laboratories Ltd’s share price declined sharply to a new 52-week low of Rs.35.06 on 24 March 2026, marking a significant downturn amid broader market fluctuations and company-specific performance concerns.

Gujarat Terce Laboratories Ltd’s share price declined to a fresh 52-week low of Rs.36.06 today, marking a significant downturn amid ongoing market pressures and company-specific factors. This new low reflects a continuation of the stock’s underperformance relative to the broader market and its sector peers.

Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Terce Laboratories Ltd has reported a flat financial performance for the quarter ended December 2025, marking a significant shift from its previously positive growth trajectory. Despite a modest increase in profit after tax (PAT) over the last six months, the company’s overall financial trend score has deteriorated sharply, reflecting challenges in sustaining revenue growth and margin expansion in a competitive pharmaceutical sector.

Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹33.00 crores, has reported deeply concerning quarterly results that highlight mounting operational challenges. The company's net profit collapsed by 71.88% quarter-on-quarter in Q2 FY26 to ₹0.45 crores, whilst posting a modest year-on-year improvement of 21.62%. The stock, trading at ₹46.34, has plunged 43.76% over the past year, significantly underperforming both the Sensex and the broader pharmaceuticals sector.

Gujarat Terce Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 19 Jan 2026, reflecting deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite some recent positive financial results and rising promoter confidence.

Gujarat Terce Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators from mildly bearish to sideways, signalling a potential stabilisation in price action. However, the company’s fundamental challenges, including weak long-term growth and expensive valuation metrics, continue to weigh on investor sentiment.

Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Dec 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 December 2025, providing investors with the latest insights into the company’s fundamentals, valuation, financial trend, and technical outlook.